| Basics |
Theravance Biopharma, Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.
|
| IPO Date: |
May 16, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$939.97M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.40 | 2.12%
|
| Avg Daily Range (30 D): |
$0.35 | 2.08%
|
| Avg Daily Range (90 D): |
$0.24 | 1.64%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.33M |
| Avg Daily Volume (30 D): |
.44M |
| Avg Daily Volume (90 D): |
.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
92 |
| Avg Trade Size (Sh.) (30 D): |
47 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Inst.Trades: |
2,114 |
| Avg Inst. Trade: |
$1.39M |
| Avg Inst. Trade (30 D): |
$1.22M |
| Avg Inst. Trade (90 D): |
$1.07M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.15M |
| Avg Closing Trade (30 D): |
$1.05M |
| Avg Closing Trade (90 D): |
$.88M |
| Avg Closing Volume: |
73.43K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.58
|
$.07
|
|
|
Diluted EPS
|
$.57
|
$.07
|
|
|
Revenue
|
$ 80.33M
|
$ 19.99M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 29.34M
|
$ 3.62M
|
$
|
|
Operating Income / Loss
|
$ -32.81M
|
$ -6.46M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 151.4M
|
$
|
$
|
|
PE Ratio
|
32.40
|
|
|
|
|
|
